Tocilizumab for the Treatment of Behcet's Syndrome

Trial Profile

Tocilizumab for the Treatment of Behcet's Syndrome

Phase of Trial: Phase IV

Latest Information Update: 11 Oct 2017

At a glance

  • Drugs Tocilizumab (Primary)
  • Indications Behcet's syndrome
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Nov 2013 Status changed from recruiting to discontinued as reported by
    • 01 Oct 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top